SavedAdd your journal

Journals / Turkish Journal of Cancer / 2003 / Cilt: 33 - Sayı: 4

Single agent oral etoposide in recurrent or advanced solid tumors

Aytuğ ÜNER
Uğur COŞKUN
Arzu YEĞİN
Deniz YAMAÇ
Nazan GÜNEL
Pages
187–190
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Oral etoposide may be a treatment choice for patients with refractory disease which there was no other alternative without supportive care.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Prolonged oral etoposide has antitumor activity in a variety of solid tumors including small cell and non-small-cell lung cancer.
📊
Key Findings & Data:A total of 53 patients have been treated with prolonged oral etoposide at a dosage of 50-100 mg/day for 5, 7,10 or 14 days in a 21 days interval.
💡
Conclusion & Impact:Oral etoposide may be a treatment choice for patients with refractory disease which there was no other alternative without supportive care.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Etoposid · İlaç uygulama programı · Karsinom

Abstract

Prolonged oral etoposide has antitumor activity in a variety of solid tumors including small cell and non-small-cell lung cancer. A total of 53 patients have been treated with prolonged oral etoposide at a dosage of 50-100 mg/day for 5, 7,10 or 14 days in a 21 days interval. The results of these patients were retrospectively evaluated. Twelve patients had small cell lung carcinoma (SCLC), 11 patients had non-small cell lung carcinoma (NSCLC) and 30 patients had different solid tumors including gastric, breast, ovarian and prostate carcinoma. Fifty-two patients were evaluated for response analysis. Objective response rate was found to be 19,2% (1,9% complete response (CR), 17,3% partial response (PR)). Stable disease was achieved in 30,8% of the patients. Grade 3 and 4 neutropenia occurred in 9,3% of the patients. We demonstrated a modest activity of single agent oral etoposide in our heterogenous group of patients with advanced and refractory disease. Oral etoposide may be a treatment choice for patients with refractory disease which there was no other alternative without supportive care.

🔖

Cite This Article

ÜNER, A., COŞKUN, U., YEĞİN, A., YAMAÇ, D., GÜNEL, N. (2003). Single agent oral etoposide in recurrent or advanced solid tumors. Turkish Journal of Cancer, Cilt: 33 - Sayı: 4, 187–190. https://ajindex.com/articles/368476

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Ross W, Rowe T, Glisson B, et al. The role of topoisomerase- II in mediating epipodophyllotoxin-induced DNA cleavage. Cancer Res 1984;44:5857-60
  2. Einhorn LH. Initial therapy with cisplatin+VP-16 in small cell lung cancer. Semin Oncol 1986;13:5-9
  3. Waits TM, Jonson DH, Hainsworth JD, et al. Prolonged administration of oral etoposide in non-small cell lung cancer: a phase II trial. J Clin Oncol 1992;10:292-6
  4. Hoskins PJ, Swenerton KD. Oral etoposide is active against platinium resistant epithelial ovarian cancer. J Clin Oncol 1994;12:60-3
  5. Atienza DM, Vogel L, Trock B, et al. Phase II study of oral etoposide for patients with advanced breast cancer. Cancer 1995;76:2485-90
  6. Williams SD, Birch R, Einhorn LH, et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin and either vinblastine or etoposide. N Engl J Med 1987;316:1435-40
  7. Grunberg SM, Felman IE, Gala KV, et al. Phase II study of etoposide (VP-16) in the treatment of advanced head and neck cancer. Am J Clin Oncol (CCT) 1985;8:393-5
  8. Slevin ML. Low-dose oral etoposide: a new role for and old drug? J Clin Oncol 1990;8:1607-9
  9. Hainsworth JD, Johnson DH, Greco FA. Chronic daily administration of oral etoposide in refractory lymphoma: A phase II trial. Eur J Cancer 1990;26:818-21
  10. Hussian MH, Pinta KJ, Redman BG, et al. Oral etoposide in the treatment of hormone-refractory prostate cancer. Cancer 1994;74:100-3
  11. Johnson DH, Greco FA, Strupp J, et al. Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: A phase II trial. J Clin Oncol 1990;8:1613-7
  12. Markmann M, Hakes T, Reichman B, et al. Phase 2 trial of chronic low-dose oral etoposide as salvage therapy of platinium- refractory ovarian cancer. J Cancer Res Clin Oncol 1992;119:55-7
  13. Martin M, Lluch A, Csado A, et al. Clinical activity of chronic oral etoposide in previously treated metastatic breast cancer. J Clin Oncol 1994;12:986-91
  14. Miller JC, Loehrer PJ, Williams SD, et al. Phase II study of oral VP-16 in refractory germ cell tumors. Proc Am Soc Clin Oncol 1989;8:145
  15. Rose PG, Blessing JA, Le LV, et al. Prolonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study. Gynecol Oncol 1998;70:263-6 16. Comis RL, Friedland DM., Good BC. The role of oral etoposide in non-small cell lung carcinoma. Drugs 1999;3:21-30
  16. Ajani JA, Takiuchi H. Recent developments in oral chemotherap